Arena Pharmaceuticals Beats Estimates On Fourth Quarter Earnings

San Diego-based Arena Pharmaceuticals, Inc. (ARNA) reported revenues of $15.4 million versus $69 million for the same time period last year. The company recorded a net loss of $13.7 million or $0.35 per share for the fourth quarter easily beating the estimate for a loss of $0.59 per share, but worse than last year’s net income of $38 million or $1.59 per share.

For the full-year, Arena delivered revenues of $21.3 million, a huge drop from 2016’s revenues of $92 million. The company recorded a net loss of $91.4 million or $2.77 per share;  a whopping increase over last year’s loss of $22 million or $0.93 per share. On December 31, 2017, Arena had cash and cash equivalents and investments totaling $271.3 million.

“We’ve made significant progress in 2017, achieving the clinical and corporate objectives we set forth as a new team,” said Amit D. Munshi, president, and CEO of Arena.  “Our focus remains on advancing our potentially best-in-class or best-in-disease pipeline and driving further value in the Company. We look forward to the etrasimod Phase 2 data readout this month and are enthusiastic about the Phase 3 clinical program for ralinepag, which we expect to begin in the second half of 2018.”

 The most advanced investigational clinical programs for Arena are ralinepag (APD811), which will be commencing a Phase 3 program for pulmonary arterial hypertension (PAH), and etrasimod (APD334), which is in Phase 2 for a broad range of immune and inflammatory conditions.  Arena is also evaluating APD371 in Phase 2 for the treatment of pain associated with Crohn’s disease. In addition, Arena has collaborations with the following pharmaceutical companies: Everest Medicines Limited (ralinepag and etrasimod in Greater China and select Asian countries), Axovant Sciences GmbH (nelotanserin – Phase 2), Boehringer Ingelheim International GmbH (undisclosed target – preclinical), and Eisai Co., Ltd. and Eisai Inc. (BELVIQ® – marketed product).

Arena stock was up over 4% in pre-market trading to $41. It is nearing its 52-week high of $44.50 and the stock moves further away from its 52-week low of $11.30. Eight analysts cover the stock with five at a buy rating and three with a hold rating.

Debra Borchardt

Debra Borchardt is the Co-Founder, and Executive Editor of GMR. She has covered the cannabis industry for several years at Forbes, Seeking Alpha and TheStreet. Prior to becoming a financial journalist, Debra was a Vice President at Bear Stearns where she held a Series 7 and Registered Investment Advisor license. Debra has a Master's degree in Business Journalism from New York University.

Leave a Reply

Your email address will not be published. Required fields are marked *

Get the latest cannabis news delivered right to your inbox

The Morning Rise

Unpack the industry with the daily cannabis newsletter for business leaders.

 Sign up

About Us

The Green Market Report focuses on the financial news of the rapidly growing cannabis industry. Our target approach filters out the daily noise and does a deep dive into the financial, business and economic side of the cannabis industry. Our team is cultivating the industry’s critical news into one source and providing open source insights and data analysis


Recent Tweets

Get the latest cannabis news delivered right to your inbox

The Morning Rise

Unpack the industry with the daily cannabis newsletter for business leaders.